By Fineline Cube 
Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.
Regulatory Approval Timeline
| Date | Jurisdiction | Indication | Key Differentiator |
|---|---|---|---|
| Oct 2024 | China | Relapsed/refractory MCL (≥2 prior therapies, including BTKi) | First approval globally |
| Feb 2026 | China | Second-line CLL/SLL | Earlier treatment line expansion |
| Jun 2026 | EU (CHMP) | All-line CLL regardless of BTKi prior use | Unprecedented treatment flexibility |
Drug Profile & Mechanism of Action
- Molecule: Pirtobrutinib (Jaypirca)
- Class: Highly selective, non-covalent (reversible) BTK inhibitor
- Key Innovation: Maintains efficacy in patients who have developed resistance to covalent BTK inhibitors
- Commercial Partnership: Innovent Biologics holds commercialization rights in mainland China
- Therapeutic Advantage: Reversible binding allows for sustained target inhibition without permanent enzyme modification
Strategic Market Positioning
| Competitive Landscape | Jaypirca Advantage |
|---|---|
| Covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) | Effective in covalent BTKi-resistant patients |
| Treatment sequencing limitations | Approved for all lines of therapy without prior treatment restrictions |
| Resistance development | Non-covalent mechanism overcomes common resistance mutations |
The CHMP recommendation represents a significant expansion beyond current BTK inhibitor paradigms, which typically require specific prior treatment sequences or exclude patients with BTK inhibitor resistance.
Commercial Implications
- Market Expansion: Unrestricted line-of-therapy approval captures broader patient population across treatment continuum
- Competitive Differentiation: Only BTK inhibitor approved regardless of prior BTK inhibitor exposure
- Revenue Trajectory: Builds on established China approvals with European market entry potential
- Partnership Value: Strengthens Innovent Biologics’ position in China’s hematologic malignancy market
- Next Steps: European Commission final decision expected within 67 days of CHMP positive opinion
This all-line approval positions Jaypirca as a potential new standard of care in CLL treatment, offering clinicians unprecedented flexibility in treatment sequencing and addressing a critical unmet need in BTK inhibitor-resistant disease.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and market adoption patterns.-Fineline Info & Tech